Loading
companiesCompany
Lux Capital
A New York venture firm that backs deep technology companies, from defence and AI to biology. Its biotech holdings include the AI drug discovery company Recursion and the imaging-based drug hunter Eikon Therapeutics.
Overview
Lux Capital was founded in 2000 by Peter Hebert, Robert Paull and Josh Wolfe and is based in New York (Wikipedia). Its tagline is 'We turn sci-fi into sci-fact' and its companies page mixes defence (Anduril), AI (Hugging Face, Cognition) and space with life sciences. Biology-related holdings on the companies page are Recursion Pharma (high-throughput biology and machine learning for drug discovery, which runs oncology programmes), Eikon Therapeutics (single-molecule live-cell imaging for drug discovery), Kallyope (gut-brain axis), eGenesis (gene-edited organs) and Benchling (R&D software). Lux is a generalist rather than an oncology specialist, and its page does not describe disease areas, so its relevance to cancer is indirect.
Portfolio (1)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Trial Library San Francisco, CA, US | Startup | ai software | Series A 2025, $10M |
Notes
top- No company on the fetched Lux pages is described as oncology-focused; Recursion and Eikon are cited as drug discovery platforms with cancer programmes known from elsewhere.